Compare BridgeBio Pharma Inc (BBIO) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Huntington Ingalls Industries Inc — how do they compare? BridgeBio Pharma Inc trades at $82.34 (market cap $16.46B), while Huntington Ingalls Industries Inc trades at $277.63 (market cap $11.03B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 1.97% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HII | |
|---|---|---|
Market Cap | $16.46B | $11.03B |
Sector | Health | Technology |
52-Week High | $90.17 | $453.73 |
52-Week Low | $44.81 | $252.93 |
Enterprise Value | $18.02B | $13.75B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
HII trades at $284.86, down 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows stable fundamentals with a P/E of 18.19 and net income margin of 4.71%, supported by recent earnings beats. Recent news highlights contract awards and leadership additions, reinforcing its defense sector presence.
The outlook is cautiously optimistic with a consensus price target of $354.50, implying significant upside. Risks include execution on new contracts and defense budget dependencies, but analyst sentiment leans positive with 44% buy ratings. The upcoming Q2 2026 earnings report on July 30 will be a key catalyst for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
